Revance agrees to lower take-private offer by Crown Labs
Adds details on deal throughout, background in paragraphs 2, 4-7
Dec 9 (Reuters) -Crown Laboratories would buy the anti-wrinkle injection maker Revance Therapeutics RVNC.O at a roughly 50% lower price compared to an original agreement signed in August, the companies said on Monday, sending the latter's stock tumbling 20%.
The lowered takeover price follows months of delay in the deal after Revance, which makes a rival to AbbVie's ABBV.N blockbuster product Botox, faced a dispute with its partner Teoxane.
As per the current agreement, Crown will buy all of Revance's outstanding shares for $3.10 per share, or $325.20 million according to Reuters' calculations. The previous agreement was for $6.66 per share or $924 million.
Revance received a notice in September for breaching the maximum allowed buffer stock levels and not adequately promoting and selling Teoxane's dermal fillers, as required by their distribution agreement.
While Revance denied the allegations, the notice prompted it and Crown to extend the closing date of the deal first announced in August.
Revance and Teoxane in October agreed to revised brand guidelines and minimum purchase commitments through 2029.
"This significant devaluation is a reflection of multiple forced errors, starting with the failed launch strategy for Daxxify and ensuing reputational damage to Revance's relationships to the surprise merger announcement near all-time lows, then leading to accusations of breach of contract with Teoxane," said Stifel analyst Annabel Samimy.
Revance initially set a premium price for Daxxify, its rival to Botox, claiming it lasts twice as long. However, last year, the company reduced the price to match Botox after having difficulty attracting customers.
In the first nine months of 2024, Revance earned $177.2 million from its products and had forecast $280 million in sales for the year in June, an outlook it withdrew in November.
The companies expect the transaction to close in the first quarter of 2025.
Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
